Main Sequence Ventures
Jason Whitfield is an accomplished professional in the field of synthetic biology and investment, currently serving as an Investment Associate at Main Sequence since October 2023, focusing on deep tech companies in the APAC region. With experience as a Non Executive Director and Co-founder of the Australasian SynBio Challenge, and having held the role of Program Manager for SynBio 10x at UNSW Founders, Jason has demonstrated leadership in fostering innovation and collaboration in the synthetic biology community. Prior to these roles, Jason was a CSIRO Synthetic Biology FSP Postdoctoral Fellow at the University of Queensland, where research centered on developing novel biosensor platforms. Jason's academic background includes a Doctor of Philosophy in Chemistry and a Bachelor of Science (BSc) in Biochemistry from The Australian National University and the University of Canterbury, respectively.
Main Sequence Ventures
2 followers
We are Australia’s deep tech investment fund tackling the world’s biggest challenges by turning today’s scientific discoveries into tomorrow’s industries. Main Sequence works closely with scientists, researchers and industry collaborators to create, fund and accelerate new companies and industries that accelerate humanity for a more prosperous future. Main Sequence was set up in 2017 to manage the CSIRO Innovation Fund, founded by the Australian Government and the national science agency to reinvest its historic contributions into the successes of the future. Over the past four years, Main Sequence has invested in 39 companies changing the way healthcare is delivered, food is produced, spaces are connected and more. These investments have led to more than 60 company collaborative projects with universities and 19 projects with CSIRO.